X2254

XE-991

≥98% (HPLC), powder, KCNQ channel blocker

• Synonym(e): 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone
• Empirische Formel (Hill-System): C₂₆H₂₀N₂O
• CAS-Nummer: 122955-42-4
• Molekulargewicht: 376.45
• MDL-Nummer: MFCD05662331
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329830775
• NACRES: NA.77

Eigenschaften

• product name: XE-991, ≥98% (HPLC)
• Assay: ≥98% (HPLC)
• Farbe: white to beige
• Löslichkeit: DMSO: >20 mg/mL
• Ersteller: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Lagertemp.: 2-8°C
• SMILES String: O=C1c2ccccc2C(Cc3ccncc3)(Cc4ccncc4)c5ccccc15
• InChI: 1S/C26H20N2O/c29-25-21-5-1-3-7-23(21)26(17-19-9-13-27-14-10-19,18-20-11-15-28-16-12-20)24-8-4-2-6-22(24)25/h1-16H,17-18H2
• InChIKey: KHJFBUUFMUBONL-UHFFFAOYSA-N

Beschreibung

Anwendung

XE-991 has been used as a KCNQ (Kv7.2/7.3) inhibitor to examine whether M-current inhibition affects oxytocin receptor (TGOT) mediated depolarization. It has also been used as an KCNQ inhibitor to study the ionic mechanism responsible for the overshoot/undershoot in membrane potential in mouse cholinergic interneurons (ChIs) in the presence of tetrodotoxin (TTX).

Biochem./physiol. Wirkung

XE-991 is a KCNQ channel blocker; which is more potent than linopiridine (Cat. No. L-134).

Leistungsmerkmale und Vorteile

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H315,H319,H335
• P-Sätze: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• Gefahreneinstufungen: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Zielorgane: Respiratory system
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable